• Skip to main navigation
  • Skip to main content
  • Skip to Footer
  • English
    • Français
  • Canada
    • Sandoz Site Directory
Sandoz : A Novartis Division
  • Our Work
    • What We Do
    • Quality Generics
    • Biopharmaceuticals
    • Specialty Products
  • About Us
    • Who We Are
    • Corporate Responsibility
    • Doing Business Responsibly
    • Contact Us
    • Grants, Donations and Sponsorships
  • Products
    • Consumers
    • Patients
    • Healthcare Professionals
    • Patient Support Programs
  • News
    • Media Releases
    • Media Resource Center
    • Stay Up-To-Date
  • Careers
    • Available Positions
    • Join the Sandoz Manufacturing team in Boucherville
    • Our Benefits
    • Employee Testimonials
    • Our Values and Vision
    • Diversity & Inclusion
Search
  • TwitterTweet
  • FacebookShare
  • Share
    • Twitter
    • Facebook
    • LinkedIn
    • Email
  • Jump to Comments
Stories/Global Impact

Biosimilars reimbursement update

As of September 30, 2020, PrZiextenzo® (pegfilgrastim) and PrRiximyo®(rituximab for injection) are now eligible for reimbursement in Quebec through the RAMQ’s Public Prescription Drug Insurance Plan.

In addition, both biosimilars are on the list of medicines and establishments for use in Canadian hospitals.

As of October 7, 2020, PrRiximyo® is also eligible for reimbursement in Nova Scotia through the Nova Scotia Pharmacare.

For more information on Sandoz biosimilars click here and to get evidence-based information on biosimilars in Canada visit The Biosimilars Generation web site.

Oct 19, 2020

Biosimilars reimbursement update

As of September 30, 2020, PrZiextenzo® (pegfilgrastim) and PrRiximyo®(rituximab for injection) are now eligible for reimbursement in Quebec through the RAMQ’s Public Prescription Drug Insurance Plan.

In addition, both biosimilars are on the list of medicines and establishments for use in Canadian hospitals. 

As of October 7, 2020, PrRiximyo® is also eligible for reimbursement in Nova Scotia through the Nova Scotia Pharmacare.

For more information on Sandoz biosimilars click here and to get evidence-based information on biosimilars in Canada visit The Biosimilars Generation web site.

    • TwitterTweet
    • FacebookShare
    • Share
      • Twitter
      • Facebook
      • LinkedIn
      • Email
    • Jump to Comments
  • Print
  • Save

Novartis Stories

View all

Global Impact

Sandoz Canada completes its 5th biosimilar launch with new biosimilar Hyrimoz® (adalimumab)

Global Impact

Sandoz Canada launches the first generic versions of two original drugs: PrSandoz® Posaconazole and PrSandoz® Silodosin

Global Impact

2021 Top Employer Canada

You are here

  1. Home ›
  2. Global Impact ›

Sandoz Canada

  • Our Work
  • About Us
  • Products
  • News
  • Careers
  • Contact Us
  • Office Locations
  • Stay up to date

Subscribe to Sandoz

  • Facebook
  • Twitter
  • YouTube
  • LinkedIn
  • RSS
  • Sandoz Site Directory
© 2021 Sandoz AG

This site is intended for an audience in Canada

  • Terms of Use
  • Privacy Policy
  • Terms of Trade
  • Return Policy